In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on PolarityTE (PTE), with a price target of $3.00. The company’s shares closed last Tuesday at $1.09.
According to TipRanks.com, Byrnes has 0 stars on 0-5 stars ranking scale with an average return of -8.6% and a 36.0% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Oncternal Therapeutics, Aridis Pharmaceuticals, and Adamas Pharmaceuticals.
Currently, the analyst consensus on PolarityTE is a Moderate Buy with an average price target of $3.00.
See today’s analyst top recommended stocks >>
Based on PolarityTE’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $3.34 million and GAAP net loss of $7.08 million. In comparison, last year the company earned revenue of $1.4 million and had a GAAP net loss of $22.98 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PolarityTE, Inc. is a commercial-stage biotechnology and regenerative biomaterials company, which focuses on discovering, designing and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Its products include SkinTE, OsteoTE and Real Time Assistant. The company was founded on May 8, 1998 and is headquartered in Salt Lake City, UT.
